FiercePharmaAsia—Takeda's workforce rejig and Velcade patent win, China's insurance drug list | Fierce Pharma
It's confirmed: Amarin loses Vascepa patent appeal, putting generics defense on life support | Fierce Pharma
Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS - Bloomberg
Biogen takes another blow as appeal for Tecfidera patent revival falls short | Fierce Pharma
Novartis loses appeal for patent on multiple sclerosis drug (NYSE:NVS) | Seeking Alpha
Stampeding generics expected to trample Lilly's now-off-patent ADHD med Strattera | Fierce Pharma
Novartis dodges Gilenya kickback claims—again
Gilead's $3B Truvada will face generics a year early. Can Descovy still win over its patients? | Fierce Pharma
Novartis wins Supreme Court temporary reprieve on Gilenya generics (NYSE:NVS) | Seeking Alpha
/cloudfront-us-east-2.images.arcpublishing.com/reuters/52AGE63A7FL7ZKCF7MWDNTV7QQ.jpg "U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug | Reuters")
U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug | Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/4SADGYNDOJLEBHXQYSBDSEA5AI.jpg "Novartis loses in patent appeal over multiple sclerosis drug | Reuters")
Novartis loses in patent appeal over multiple sclerosis drug | Reuters
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court | Fierce Pharma
Riding on patent office win, Novartis takes Gilenya generics fight to court | Fierce Pharma
Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS - Bloomberg
Novartis loses in patent appeal over multiple sclerosis drug Gilenya | The Financial Express
Novartis dealt another blow in ongoing Gilenya patent feud
Novartis' Gilenya staves off generic challengers—for now—after federal injunction | Fierce Pharma
/cloudfront-us-east-2.images.arcpublishing.com/reuters/UQPIK3T2DVOX7EIO4QZCM5HIAA.jpg "Novartis loses in patent appeal over multiple sclerosis drug | Reuters")
Novartis loses in patent appeal over multiple sclerosis drug | Reuters
Bristol Myers Squibb's Zeposia launches into crowded MS market | Fierce Pharma
Alembic Pharma (Oral Solids ==> Injectables, Onco, Derma, Opthalmic) - Not-so-Hidden Gems - ValuePickr Forum
Lilly fends off Cialis generics with new patent settlement | Fierce Pharma
After win at patent office, Bristol Myers inks Revlimid deal with Dr. Reddy's | Fierce Pharma
Novartis could snag a blockbuster MS market all for itself, just in time to fight Gilenya generics | Fierce Pharma
